Differential Impact of Fractional Flow Reserve Measured After Coronary Stent Implantation by Left Ventricular Dysfunction.

drug-eluting stent(s) fractional flow reserve left ventricular ejection fraction percutaneous coronary intervention prognosis

Journal

JACC. Asia
ISSN: 2772-3747
Titre abrégé: JACC Asia
Pays: United States
ID NLM: 9918452380106676

Informations de publication

Date de publication:
Mar 2024
Historique:
received: 03 08 2023
revised: 06 10 2023
accepted: 18 10 2023
medline: 11 3 2024
pubmed: 11 3 2024
entrez: 11 3 2024
Statut: epublish

Résumé

Both left ventricular systolic function and fractional flow reserve (FFR) are prognostic factors after percutaneous coronary intervention (PCI). However, how these prognostic factors are inter-related in risk stratification of patients after PCI remains unclarified. This study evaluated differential prognostic implication of post-PCI FFR according to left ventricular ejection fraction (LVEF). A total of 2,965 patients with available LVEF were selected from the POST-PCI FLOW (Prognostic Implications of Physiologic Investigation After Revascularization with Stent) international registry of patients with post-PCI FFR measurement. The primary outcome was a composite of cardiac death or target-vessel myocardial infarction (TVMI) at 2 years. The secondary outcome was target-vessel revascularization (TVR) and target vessel failure, which was a composite of cardiac death, TVMI, or TVR. Post-PCI FFR was independently associated with the risk of target vessel failure (per 0.01 decrease: HR Post-PCI FFR had differential prognostic impact according to LVEF. Residual ischemia by post-PCI FFR ≤0.80 was a prognostic indicator for cardiac death or TVMI among patients with patients with LVEF ≤40%, and it was associated with TVR among patients with patients with LVEF>40%. (Prognostic Implications of Physiologic Investigation After Revascularization with Stent [POST-PCI FLOW]; NCT04684043).

Sections du résumé

Background UNASSIGNED
Both left ventricular systolic function and fractional flow reserve (FFR) are prognostic factors after percutaneous coronary intervention (PCI). However, how these prognostic factors are inter-related in risk stratification of patients after PCI remains unclarified.
Objectives UNASSIGNED
This study evaluated differential prognostic implication of post-PCI FFR according to left ventricular ejection fraction (LVEF).
Methods UNASSIGNED
A total of 2,965 patients with available LVEF were selected from the POST-PCI FLOW (Prognostic Implications of Physiologic Investigation After Revascularization with Stent) international registry of patients with post-PCI FFR measurement. The primary outcome was a composite of cardiac death or target-vessel myocardial infarction (TVMI) at 2 years. The secondary outcome was target-vessel revascularization (TVR) and target vessel failure, which was a composite of cardiac death, TVMI, or TVR.
Results UNASSIGNED
Post-PCI FFR was independently associated with the risk of target vessel failure (per 0.01 decrease: HR
Conclusions UNASSIGNED
Post-PCI FFR had differential prognostic impact according to LVEF. Residual ischemia by post-PCI FFR ≤0.80 was a prognostic indicator for cardiac death or TVMI among patients with patients with LVEF ≤40%, and it was associated with TVR among patients with patients with LVEF>40%. (Prognostic Implications of Physiologic Investigation After Revascularization with Stent [POST-PCI FLOW]; NCT04684043).

Identifiants

pubmed: 38463680
doi: 10.1016/j.jacasi.2023.10.009
pii: S2772-3747(23)00300-9
pmc: PMC10920040
doi:

Banques de données

ClinicalTrials.gov
['NCT04684043']

Types de publication

Journal Article

Langues

eng

Pagination

229-240

Informations de copyright

© 2024 The Authors.

Déclaration de conflit d'intérêts

Dr Joo Myung Lee has received an institutional research grant from Abbott Vascular, Boston Scientific, Philips Volcano, Terumo Corporation, Donga-ST, and Zoll Medical. Dr Bon-Kwon Koo has received an institutional research grant from St. Jude Medical (Abbott Vascular) and Philips Volcano. Dr Joon Hyung Doh has received a research grant from Philips Volcano. Dr Shao-Liang Chen is a consultant for Microport and Boston Scientific International; and has received a grant from the National Natural Scientific Foundation of China. Dr Toth receives consultancy fees and unrestricted research grants from Abbott, Medtronic, and Terumo. Dr Johnson has received institutional research support from Volcano/Philips (DEFINE-FLOW, NCT02328820), Abiomed (for study of Impella-related coronary physiology) and St. Jude Medical (CONTRAST, NCT02184117); has an institutional licensing agreement with Boston Scientific for the smart-minimum FFR algorithm commercialized under 510(k) K191008; and has pending patents on diagnostic methods for quantifying aortic stenosis and TAVR physiology, and also algorithms to correct pressure tracings from fluid-filled catheters. Dr Leesar has received an institutional research grant from ACIST. Dr Azzalini has received honoraria from Teleflex, Abiomed, GE Healthcare, Asahi Intecc, Philips, Abbott Vascular, and Cardiovascular System, Inc. Dr Diletti has received an institutional research grant to Erasmus University Medical Center; and has served as a consultant to ACIST Medical Systems. Dr Collison has received consultancy/speaker fees from Abbott. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Auteurs

Ki Hong Choi (KH)

Division of Cardiology, Department of Internal Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Woochan Kwon (W)

Division of Cardiology, Department of Internal Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Doosup Shin (D)

Division of Cardiology, Department of Internal Medicine, Duke University Medical Center, Durham, North Carolina, USA.

Seung-Hun Lee (SH)

Division of Cardiology, Department of Internal Medicine, Heart Center, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea.

Doyeon Hwang (D)

Department of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, Seoul, Korea.

Jinlong Zhang (J)

Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.

Chang-Wook Nam (CW)

Department of Medicine, Keimyung University Dongsan Medical Center, Daegu, Korea.

Eun-Seok Shin (ES)

Department of Cardiology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.

Joon-Hyung Doh (JH)

Department of Medicine, Inje University Ilsan-Paik Hospital, Goyang, Korea.

Shao-Liang Chen (SL)

Division of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.

Tsunekazu Kakuta (T)

Division of Cardiovascular Medicine, Tsuchiura Kyodo General Hospital, Ibaraki, Japan.

Gabor G Toth (GG)

University Heart Centre Graz, Medical University Graz, Austria.

Zsolt Piroth (Z)

Gottsegen National Cardiovascular Centre, Budapest, Hungary.

Abdul Hakeem (A)

Division of Cardiovascular Diseases and Hypertension, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, New Jersey, USA.

Barry F Uretsky (BF)

Central Arkansas VA Health System/University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.

Yohei Hokama (Y)

Department of Cardiology, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan.

Nobuhiro Tanaka (N)

Department of Cardiology, Ajou University School of Medicine, Suwon, Korea.

Hong-Seok Lim (HS)

Department of Cardio-Renal Medicine and Hypertension, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

Tsuyoshi Ito (T)

Department of Cardiology, Kyoto Second Red Cross Hospital, Kyoto, Japan.

Akiko Matsuo (A)

Division of Cardiology, Department of Medicine, University of Washington, Seattle, Washington, USA.

Lorenzo Azzalini (L)

Division of Cardiovascular Diseases, University of Alabama, Birmingham, Alabama, USA.

Massoud A Leesar (MA)

Department of Interventional Cardiology, Thoraxcenter, Erasmus University Medical Centre, Rotterdam, the Netherlands.

Joost Daemen (J)

West of Scotland Regional Heart and Lung Centre, Golden Jubilee National Hospital, Glasgow, United Kingdom.

Damien Collison (D)

Cardiovascular Center Aalst, Aalst, Belgium.

Carlos Collet (C)

Department of Cardiology, University of Lausanne, Switzerland.

Bernard De Bruyne (B)

Department of Cardiology, University of Lausanne, Switzerland.

Bon-Kwon Koo (BK)

Department of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, Seoul, Korea.

Taek Kyu Park (TK)

Division of Cardiology, Department of Internal Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Jeong Hoon Yang (JH)

Division of Cardiology, Department of Internal Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Young Bin Song (YB)

Division of Cardiology, Department of Internal Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Joo-Yong Hahn (JY)

Division of Cardiology, Department of Internal Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Seung-Hyuk Choi (SH)

Division of Cardiology, Department of Internal Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Hyeon-Cheol Gwon (HC)

Division of Cardiology, Department of Internal Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Joo Myung Lee (JM)

Division of Cardiology, Department of Internal Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Classifications MeSH